(Reuters) – Advisers to the U.S. Food and Drug Administration on Thursday unanimously backed the use of updated COVID-19 vaccines that would target an XBB Omicron subvariant of the coronavirus for the 2023-2024 vaccination campaign.
The panel voted 21-0 in favor XBB-tailored shots.
(Reporting by Bhanvi Satija and Sriparna Roy in Bengaluru and Michael Erman in New York; Editing by Bill Berkrot)
